---
document_datetime: 2023-09-21 17:42:19
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/rasilez-h-c-780-ws-37-epar-assessment-report-variation_en.pdf
document_name: rasilez-h-c-780-ws-37-epar-assessment-report-variation_en.pdf
version: success
processing_time: 18.0783074
conversion_datetime: 2025-12-19 21:30:44.61594
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

23 September 2010 EMA/CHMP/479605/2012 Human Medicines Development and Evaluation

## Assessment report

Rasilez, Riprazo, Sprimeo (aliskiren),

Rasilez HCT (aliskiren hemifumarate / hydrochlorothiazide)

Procedure No.:

EMEA/H/C/xxxx/WS/0037

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom

Telephone

+44 (0)20 7418 8400

Facsimile

+44 (0)20 7418 8613

E-mail

info@ema.europa.eu

Website

www.ema.europa.eu

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 1. Scientific discussion

## 1.1. Introduction

Aliskiren is an anti-hypertensive agent, which acts by inhibiting the enzyme renin to block the conversion of angiotensinogen to angiotensin I, the precursor of angiotensin II. Aliskiren at once daily doses of 150 and 300 mg was approved in the EU on 21 June 2007, for use as monotherapy, or in combination with other anti-hypertensive agents, for the treatment of mild to moderate hypertension.

On 20 November 2008, the new fixed combination aliskiren/hydrochlorothiazide (Rasilez HCT), was approved in the EU for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone, and as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.

Based on preclinical data, it is known that P-gp is a major determinant of aliskiren bioavailability. A clinical study conducted independently by Tapaninen et al. explored the pharmacokinetic interaction between aliskiren and itraconazole (a P-gp inhibitor) in healthy volunteers. The results of this study show that the exposure of aliskiren is increased by itraconazole when both drugs are administered concomitantly.

This application concerns the following medicinal products:

| Medicinal product:   | International non-proprietary name:          | Presentations:   |
|----------------------|----------------------------------------------|------------------|
| Rasilez              | aliskiren                                    | See Annex A      |
| Rasilez HCT          | aliskiren hemifumarate / hydrochlorothiazide | See Annex A      |
| Riprazo              | aliskiren                                    | See Annex A      |
| Sprimeo              | aliskiren                                    | See Annex A      |

The variation requested is the following:

| Variations requested   |                                                                                                                                                                              | Type   |
|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| C.I.4                  | Variations related to significant modifications of the Summary of Product Characteristics due in particular to new quality, pre-clinical, clinical or pharmacovigilance data | II     |

This type II variation concerns an update of section 4.3 of the SPC to add a contraindication for the concomitant use of aliskiren and itraconazole, and section 4.5 of the SPC to add information regarding this interaction following the publication of a study in healthy subjects. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to update the annexes in line with the latest QRD template (version 7.3).

This application was submitted for a Type II variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.

<div style=\"page-break-after: always\"></div>

## 1.2. Clinical aspects

## Interaction study in healthy volunteers

Tapinen and co-workers performed a DDI study to investigate the effects of itraconazole on the pharmacokinetics (PK) and pharmacodynamics (PD) of aliskiren. In a randomized crossover study with 2 phases and a washout period of 4 weeks, healthy volunteers took either 100 mg itraconazole (first dose 200 mg) or placebo orally twice daily for 5 days. On Day 3, following an overnight fast, they received their morning dose of itraconazole or placebo. One hour later, a single oral dose of 150 mg aliskiren was administered with 150 mL of water. Blood samples were blood samples for drug concentration measurements were drawn prior to and 0.5, 1, 2, 3, 4, 5, 7, 9, 12, 24, 34, 48, and 72 hours after the administration of aliskiren. On Day 3, blood samples were also drawn (T = 0, 4 and 24 hr post dose) for the determination of plasma renin activity. On Day 3, urine was collected up to 12 hours to measure aliskiren. Systolic and diastolic blood pressures and heart rate were measured prior to and 2, 4, 7, 9, 12, and 24 hours after the administration of aliskiren.

Time-courses of aliskiren plasma levels with or without itraconazole are shown in the following figure:

Figure 1.Mean±SDplasma concentrations of aliskiren in 11 healthy volunteers aftera single150-mg oral dose of aliskiren on day3ofa5-daytreatmentwith100mgitraconazole(firstdose 200mg)or placebo twice daily.Inset depicts the same data on a semi-logarithmicscale.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Aliskiren PK parameters with or without (placebo) itraconazole are shown in the following table:

| Variable           | PlaceboPhase(Control)   | ItraconazolePhase   | GeometricMeanRatio/ MeanDifferencea(95%CI)   | PValue   |
|--------------------|-------------------------|---------------------|----------------------------------------------|----------|
| Cmax ng/mL         | 142 ± 82                | 766 ± 377           | 5.81 (3.09, 10.92)                           | <.001    |
| max, h             | 1 (0.5-5)               | 4 (2-7)             |                                              | .006     |
| t/2, h             | 34.0 ± 9.7              | 36.2 ± 8.2          | 2.0 (-7.4, 11.4)                             | .643     |
| AUCo-72 h, ng.h/mL | 565 ± 275               | 3518 ± 1353         | 6.45 (4.19, 9.92)                            | <.001    |
| AUCo-, ng.h/mL     | 625±293                 | 3957± 1458          | 6.54 (4.36, 9.81)                            | <.001    |
| Ae,mg              | 0.567±0.289             | 4.463 ± 2.079       | 8.00 (5.47, 11.69)                           | <.001    |
| CLrenal, L/h       | 1.48 ± 0.24             | 1.80 ± 0.36         | 1.21 (1.01, 1.44)                            | .042     |

Data are given as mean ± SD, tmax data as median (range). CI, confidence interval; Cmax, peak plasma concentration; tmax, time to Cmaxi 七/2, elimination half-life; AUCoz2 h, area under the plasma concentration-time curve from 0 to 72 hours; AUCo-, area under the plasma concentration-time curve from time 0 to infinity;Ae,amount excreted into urine within 12hours; CLrenal,renal clearance.

Itraconazole markedly increased aliskiren AUC and Cmax but did not change t1/2 or CL.

The Cmax and AUC0-13 h of itraconazole and hydroxyitraconazole showed no significant correlation with the relative increase in the Cmax or AUC0-∞ of aliskiren.

Plasma renin activity 24 hours after aliskiren intake was 68% lower during the itraconazole phase than during the placebo phase. No significant difference existed in the systolic or diastolic blood pressure or the heart rate between the itraconazole and placebo phases.

The authors concluded that this interaction is probably mediated by inhibition of the P-gp-mediated efflux of aliskiren in the small intestine, with a possible, minor contribution from inhibition of CYP3A4.

Considering that the reported change in aliskiren AUC induced by itraconazole in the presence of 150 mg aliskiren is higher than that with cyclosporine, the MAH's conclusion is that it is appropriate to consider itraconazole as a potent P-gp inhibitor and to advise against concomitant use in a similar manner to cyclosporine.

## Changes to the Product Information

The following changes to the current aliskiren and aliskiren/Hctz product information are proposed by the MAH:

<div style=\"page-break-after: always\"></div>

## Note for thereviewer:

- -Additionsrelated tothecontraindicationwithitraconazoleareinblue
- -Additionsrelated tonewQRD templateare ingreen
- -Deletions are inred strikethrough

| SUMMARY OFPRODUCTCHARACTERISTICS                                                                                                                                                                                                                                                                                                                                                                              | SUMMARY OFPRODUCTCHARACTERISTICS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PRESENT 10,11                                                                                                                                                                                                                                                                                                                                                                                                 | PROPOSED 10,11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 4.3 Contraindications Theconcomitantuseofaliskirenwithciclosporin,ahighly potentP-gpinhibitor,andotherpotentP-gpinhibitors (quinidine,verapamil),iscontraindicated(seesection4.5).                                                                                                                                                                                                                            | 4.3Contraindications The concomitant use ofaliskirenwithciclosporin and itraconazole,twohighlypotentP-gpinhibitors,andother potentP-gpinhibitors(quinidine,verapamil),is contraindicated (see section 4.5).                                                                                                                                                                                                                                                                                                                              |
| 4.5Interactionwithothermedicinalproductsandother formsofinteraction P-gppotentinhibitors A single dosedrug interactionstudyinhealthy subjectshas shown thatciclosporin(200and600mg)increasesCmaxof aliskiren75mgapproximately2.5-foldandAUC approximately5-fold.Theincreasemaybehigherwithhigher aliskirendoses.Therefore,concomitantuseofaliskirenand P-gppotent inhibitorsiscontraindicated(seesection4.3). | 4.5Interactionwithothermedicinalproductsandother formsofinteraction P-gppotentinhibitors A single dose druginteractionstudy in healthy subjects has shown thatciclosporin(200 and 600mg) increasesCmaxof aliskiren75mgapproximately2.5-foldandAUC approximately5-fold.Theincreasemaybehigherwithhigher aliskiren doses.In healthy subjects,itraconazole（100 mg) increasesAUCand Cmaxofaliskiren(150mg)by6.5-fold and5.8-fold,respectively.Therefore,concomitantuseof aliskirenandP-gppotentinhibitorsiscontraindicated(see section 4.3). |
| 4.6Pregnancy andlactation Lactation It isnotknownwhetheraliskirenisexcretedinhumanmilk. [Rasilez/Sprimeo/Riprazo]wassecretedinthemilkof lactatingrats.Itsuseisthereforenotrecommended in womenwhoarebreast-feeding                                                                                                                                                                                            | 4.6 Fertility,pregnancy and lactation Breast-feeding Itisnotknownwhetheraliskirenisexcretedinhumanmilk. [Rasilez/Sprimeo/Riprazo]wassecretedinthemilkof lactatingrats.Itsuseisthereforenotrecommended in womenwhoarebreast-feeding.                                                                                                                                                                                                                                                                                                      |

## RASILEZ/SPRIMEO/RIPRAZO

<div style=\"page-break-after: always\"></div>

| 4.8 Undesirableeffects Theadversedrugreactions(Table1)arerankedunder headingoffrequency,themostfrequentfirst,usingthe followingconvention:verycommon(21/10);common(≥1/100, <1/10);uncommon（≥1/1,000,<1/100);rare（≥1/10,000, <1/1,000);veryrare(<1/10,000),including-isolatedreports Withineachfrequencygrouping,undesirableeffectsare presented inorderofdecreasingseriousness Angioedemahasoccurredduringtreatmentwith [Rasilez/Sprimeo/Riprazo].Incontrolledclinicaltrials, angioedemaoccurredrarelyduringtreatmentwith [Rasilez/Sprimeo/Riprazo]withratescomparabletotreatment withplaceboorhydrochlorothiazide.Casesofangioedema havealsobeenreportedinpost-marketingexperience anallergicreaction（inparticulardifficultiesinbreathing，or swallowing,orswellinoftheface,extremities,eyes,lips and/ortongue)patientsshoulddiscontinuetreatmentand contactthephysician(seesection4.4).   | 4.8Undesirableeffects Theadversedrugreactions(Table1)arerankedunder headingoffrequency，themostfrequentfirst,usingthe followingconvention:verycommon(≥1/10);common(≥1/100, <1/10);uncommon（≥1/1,000,<1/100);rare（≥1/10,000， <1/1,000);veryrare（<1/10,000)andnotknown(cannotbe estimatedfromtheavailabledata).Withineachfrequency grouping,undesirableeffectsarepresentedinorderof decreasing seriousness. Angioedemahasoccurredduringtreatmentwith [Rasilez/Sprimeo/Riprazo].Incontrolledclinicaltrials, angioedemaoccurredrarelyduringtreatmentwith [Rasilez/Sprimeo/Riprazo]withratescomparabletotreatment withplaceboorhydrochlorothiazide.Casesofangioedema havealsobeenreportedinpost-marketingexperience anallergicreaction(inparticulardifficultiesinbreathing,or swallowing,orswellingoftheface,extremities,eyes,lips and/ortongue)patientsshoulddiscontinuetreatmentand contactthephysician(seesection4.4).   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.DATEOFREVISIONOF THETEXT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 10.DATEOFREVISIONOFTHETEXT Detailed informationonthisproductisavailableon the websiteof the European MedicinesAgency http://www.ema.europa.eu                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

## OTHERCONDITIONS

## RiskManagementPlan

AspertheCHMPGuidelineonRiskManagementSystems formedicinalproductsforhumanuse,updatedRMPshould besubmittedatthesametimeasthenextPeriodicSafety UpdateReport(PSUR).

Inaddition,anupdatedRMPshouldbesubmitted：

- Whennewinformationisreceivedthatmayimpact on thecurrentSafetySpecification, PharmacovigilancePlanorriskminimisation activities.
- Within60daysofanimportant（pharmacovigilanceor riskminimisation)milestonebeingreached.
- AttherequestoftheEMEA

## OTHERCONDITIONS

RiskManagementPlan

AspertheCHMPGuidelineonRiskManagementSystems formedicinalproductsforhumanuse,anyupdatedRMP shouldbesubmittedatthesametimeasthefollowing PeriodicSafetyUpdate Report(PSUR).

Inaddition,anupdatedRMPshouldbesubmitted:

- Whennewinformationisreceivedthatmayimpact onthecurrentSafetySpecification, PharmacovigilancePlanorriskminimisation activities.
- ·Within60daysofanimportant（pharmacovigilanceor riskminimisation)milestonebeingreached.
- At therequestof theEuropeanMedicinesAgency.

| PACKAGE LEAFLET                                                                                                                                                                                                                                                                                                                        | PACKAGE LEAFLET                                                                                                                                                                                                                                                                                                                        | PACKAGE LEAFLET                                                                                                                                                                                                                                                                                                                                                                           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PRESENT10,11                                                                                                                                                                                                                                                                                                                           | PRESENT10,11                                                                                                                                                                                                                                                                                                                           | PROPOSED 10,11                                                                                                                                                                                                                                                                                                                                                                            |
| 2.                                                                                                                                                                                                                                                                                                                                     | BEFOREYOUTAKERASILEZ/SPRIMEO/RIPRAZO                                                                                                                                                                                                                                                                                                   | 2. BEFOREYOUTAKERASILEZ/SPRIMEO/RIPRAZO                                                                                                                                                                                                                                                                                                                                                   |
| Do nottake[Rasilez/Sprimeo/Riprazo] ifyou are takingciclosporin(amedicineused in transplantationtopreventorganrejectionorforother conditions,e.g.rheumathoidarthritisoratopicdermatitis)or verapamil(amedicineused tolowerbloodpressure,to correcthearthrhythmortotreatanginapectoris)orquinidine (amedicineusedtocorrectheartrhythm). | Do nottake[Rasilez/Sprimeo/Riprazo] ifyou are takingciclosporin(amedicineused in transplantationtopreventorganrejectionorforother conditions,e.g.rheumathoidarthritisoratopicdermatitis)or verapamil(amedicineused tolowerbloodpressure,to correcthearthrhythmortotreatanginapectoris)orquinidine (amedicineusedtocorrectheartrhythm). | Donottake[Rasilez/Sprimeo/Riprazo] ifyouaretakingciclosporin(amedicineusedin transplantationtopreventorganrejectionorforother conditions,e.g.rheumathoidarthritisoratopicdermatitis) itraconazole(amedicineusedtotreatfungalinfections), verapamil(amedicineusedtolowerbloodpressure,to correcthearthrhythmortotreatanginapectoris)orquinidine (a medicine used to correct heart rhythm). |

<div style=\"page-break-after: always\"></div>

| Thisleafletwaslastapproved in                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Thisleafletwaslastapproved in Detailed informationon thismedicineisavailableon the European Medicines Agency website: http://www.ema.europa.eu                                                                                                                                                                                                                                                                                                                                      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| RASILEZHCT                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | RASILEZHCT                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| SUMMARYOFPRODUCTCHARACTERISTICS                                                                                                                                                                                                                                                                                                                                                                                                                                                   | SUMMARYOFPRODUCTCHARACTERISTICS                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| PRESENT 10,11                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | PROPOSED 10, 11                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 4.3 Contraindications Theconcomitantuseofaliskirenwithciclosporin,a highlypotentP-glycoprotein(P-gp)inhibitors,andother potentP-gpinhibitors(quinidine,verapamil),is contraindicated(see section4.5).                                                                                                                                                                                                                                                                             | 4.3Contraindications Theconcomitantuseofaliskirenwithciclosporinand itraconazole,twohighlypotentP-glycoprotein（P-gp) inhibitors,andotherpotentP-gpinhibitors（quinidine, verapamil),iscontraindicated(seesection4.5).                                                                                                                                                                                                                                                                |
| 4.5Interactionwithothermedicinalproductsandother formsofinteraction                                                                                                                                                                                                                                                                                                                                                                                                               | 4.5Interactionwithothermedicinalproductsandother forms ofinteraction                                                                                                                                                                                                                                                                                                                                                                                                                |
| P-gppotentinhibitors:Asingledosedruginteractionstudyin healthysubjectshasshownthatciclosporin(200and600mg) AUCapproximately5-fold.Theincreasemaybehigherwith higheraliskiren doses.Therefore,concomitantuseof aliskiren and P-gppotent inhibitors iscontraindicated(see section4.3).                                                                                                                                                                                              | P-gppotentinhibitors:Asingledosedruginteractionstudyin healthysubjectshasshownthatciclosporin(200and600mg) increasesCmaxofaliskiren75mgapproximately2.5-foldand AUCapproximately5-fold.Theincreasemaybehigherwith higher aliskiren doses.Inhealthy subjects,itraconazole (100 mg) increasesAUC and Cmaxofaliskiren(150mg) by 6.5-foldand5.8-fold,respectively.Therefore,concomitant useofaliskirenandP-gppotentinhibitorsiscontraindicated (see section 4.3).                       |
| 4.6 Pregnancyandlactation                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 4.6 Fertility,pregnancy andlactation                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Lactation RasilezHCTiscontraindicatedduringlactation(seesection 4.3).Itisnotknownwhetheraliskirenisexcretedinhuman milk.Aliskirenwassecreted inthemilkoflactatingrats. Thiazidesappearinhumanmilkandmayinhibitlactation. Theycanproduceadversebiological effectsincluding hypokalaemia,haemolysis(glucose-6-phosphate dehydrogenase(G6PD)defect)andhypersensitivitydueto sulphonamideproperties.                                                                                  | Breast-feeding RasilezHCTiscontraindicatedduringlactation(seesection 4.3).ltisnotknownwhetheraliskirenisexcretedinhuman milk.Aliskirenwassecretedinthemilkoflactatingrats. Thiazidesappear inhuman milkand mayinhibit lactation. hypokalaemia,haemolysis(glucose-6-phosphate dehydrogenase(G6PD)defect)andhypersensitivitydueto sulphonamideproperties.                                                                                                                             |
| 4.8Undesirableeffects Thefrequencyofadversereactionslistedbelowisdefined using thefollowingconvention:verycommon(21/10); common（≥1/100to<1/10);uncommon（≥1/1,000to <1/100);rare(≥1/10,000to<1/1,000);veryrare （<1/10,0o0),notknown(cannotbeestimatedfromthe effectsarepresented inorderofdecreasingseriousness. Incontrolledclinicaltrials,angioedemaoccurredrarelyduring treatmentwithaliskirenwithratescomparabletotreatment withplaceboorhydrochlorothiazide.Casesofangioedema | 4.8Undesirableeffects Thefrequencyofadversereactionslistedbelowisdefined using thefollowingconvention:verycommon(21/10); common（≥1/100to<1/10);uncommon（≥1/1,000to <1/100);rare（≥1/10,000to<1/1,000);veryrare （<1/10,000)andnotknown(cannotbeestimatedfromthe effectsarepresentedinorderofdecreasingseriousness. Incontrolledclinical trials,angioedemaoccurredrarelyduring treatmentwithaliskirenwithratescomparabletotreatment withplaceboorhydrochlorothiazide.Casesofangioedema |
| havealsobeenreportedinpost-marketingexperience anallergicreactionpatientsshoulddiscontinuetreatmentand contact thephysician(seesection4.4). 10.DATEOFREVISIONOFTHETEXT                                                                                                                                                                                                                                                                                                            | havealsobeenreported inpost-marketingexperience anallergicreactionpatientsshoulddiscontinuetreatmentand contact thephysician(seesection4.4). 10.DATEOFREVISIONOFTHETEXT                                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Detailedinformationon thisproductis availableon the website of the European MedicinesAgency http://www.ema.europa.eu                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

## OTHERCONDITIONS

## RiskManagementPlan

AspertheCHMPGuidelineonRiskManagementSystems formedicinalproductsforhumanuse,updatedRMPshould besubmittedatthesametimeasthenextPeriodicSafety Update Report(PSUR).

Inaddition,anupdatedRMPshouldbesubmitted:

- Whennewinformationisreceivedthatmayimpact onthecurrentSafetySpecification, PharmacovigilancePlanorriskminimisation activities.
- Within60daysofanimportant（pharmacovigilanceor riskminimisation)milestonebeingreached.
- AttherequestoftheEMEA.

## CONDITIONS OF THE MARKETING AUTHORISATION

## OTHERCONDITIONS

## RiskManagementPlan

AspertheCHMPGuidelineonRiskManagementSystems formedicinalproductsforhumanuse,anyupdatedRMP shouldbesubmitted atthesametimeasthefollowing PeriodicSafetyUpdateReport(PSUR).

Inaddition,anupdatedRMPshouldbesubmitted:

- Whennewinformationisreceivedthatmayimpact on thecurrentSafetySpecification, PharmacovigilancePlanorriskminimisation activities.
- Within60daysofanimportant(pharmacovigilanceor riskminimisation)milestonebeingreached.
- At therequestof the European MedicinesAgency.

| PACKAGELEAFLET                                                                                                                                                                                                                                                                                                                  | PACKAGELEAFLET                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PRESENT10,11                                                                                                                                                                                                                                                                                                                    | PROPOSED 10,11                                                                                                                                                                                                                                                                                                                                                                               |
| 2. BEFOREYOUTAKERASILEZHCT ifyou aretaking ciclosporin(amedicineused in transplantationtopreventorganrejectionorforother conditions,e.g.rheumatoid arthritisoratopic dermatitis)orverapamil(amedicineusedtolower bloodpressure,tocorrecthearthrhythmortotreat anginapectoris)orquinidine(amedicineused to correctheart rhythm). | 2. BEFOREYOUTAKERASILEZHCT ifyou aretaking ciclosporin(amedicineused in transplantationtopreventorganrejectionorforother conditions,e.g.rheumatoidarthritisoratopic dermatitis),itraconazole(a medicine used to treat fungal infections),verapamil (a medicine used to lowerbloodpressure,tocorrecthearthrhythmorto treatanginapectoris)orquinidine(a medicine used to correctheart rhythm). |
| Thisleafletwaslastapprovedin                                                                                                                                                                                                                                                                                                    | This leafletwaslast approved in Detailed information on thismedicine is available on the European Medicines Agency website: http://www.ema.europa.eu                                                                                                                                                                                                                                         |

## Overall discussion and benefit/risk assessment

The data from the study in healthy volunteers by Tapinen et al. further demonstrate that P-gp status has a very marked influence on the pharmacokinetics of aliskiren, thus justifying the precautionary approach to contraindicate concomitant use of aliskiren and potent P-gp inhibitors.

The addition of a contraindication for the concomitant use of itraconazole is endorsed by the CHMP and the proposed changes to section 4.3 and 4.5 of the SPC can be agreed.

The proposed changes to the annexes related to the implementation of the latest QRD template (version 7.3.1) are acceptable and the benefit/risk balance remains unchanged.

## 2. Conclusion

On 23 September 2010 the CHMP considered this Type II variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008 to be acceptable and agreed on the amendments to be introduced in the Summary of Product Characteristics, Annex II and Package Leaflet (Attachment 1 - changes highlighted).

<div style=\"page-break-after: always\"></div>

|       |                                                                                                                                                                              | Type   |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| C.I.4 | Variations related to significant modifications of the Summary of Product Characteristics due in particular to new quality, pre-clinical, clinical or pharmacovigilance data | II     |

This type II variation concerns an update of section 4.3 of the SPC to add a contraindication for the concomitant use of aliskiren and itraconazole, and section 4.5 of the SPC to add information regarding this interaction following the publication of a study in healthy subjects. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to update the annexes in line with the latest QRD template (version 7.3).